BridgeBio Aims for BBT-877 Technology Export at 'Bio Europe'

Bridge Biotherapeutics announced on the 24th that it will participate in '2024 Bio Europe,' the largest pharmaceutical and bio industry partnering event in the European region, held over three days from the 4th to the 6th of next month in Stockholm, Sweden, and will hold multiple business development partnering meetings with various companies.

Bridge Bio is currently focusing on the development of BBT-877, a drug candidate for idiopathic pulmonary fibrosis that has entered the late phase of clinical Phase 2. Among the 129 trial participants, 82 have completed the 24-week dosing procedure, and recently, the Independent Data Monitoring Committee (IDMC) comprehensively recognized the drug's safety and competitiveness, recommending that the clinical trial be completed as planned. Top-line data is scheduled to be announced in April next year. The company plans to hold numerous meetings related to this at Bio Europe.

At this year's Bio Europe, Bridge Bio also plans to continue exploring promising early-stage compounds and new target-related technologies, including new formulations. Following key clinical-stage projects targeting patients with idiopathic pulmonary fibrosis and lung cancer, the company intends to repeatedly review the potential for pipeline expansion to secure sustainable growth drivers.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, “As we enter the final stage of clinical Phase 2 for BBT-877, which is expected to have competitive safety and efficacy, business development discussions with major companies including global big pharma are progressing repeatedly. Based on the advanced research and development achievements since Bio USA held last June, we will make company-wide efforts to quickly present meaningful business development results.”

This content was produced with the assistance of AI translation services.